Clinical trials to test employment drugs to manipulate mGluR1 have yielded limited results for treatment of epilepsy, pain, Alzheimer’s, Parkinson’s, anxiety/depression (Hovelsø et al., 2012). This evidence concerns the gene GRM1 and depressive symptom measurement.